Vernalis PLC Regulatory News (VER)

1 Jun 2009 16:43



NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

VERNALIS PLC

WINNERSH, U.K 1 June 2009 Vernalis plc (LSE: VER ("Company")) announces, in accordance with DTR 3.1.2R, that it received notification on 29 May 2009 from Ms Carol Ferguson, one of the Company's non-executive directors, that 7,412 shares of 20 pence each ("Ordinary Shares") have been transferred to her Self Invested Personal Pension ("SIPP").

Accordingly, on 29 May 2009, 7,412 Ordinary Shares were sold from her nominee account at a price of £0.654 per share and 7,412 Ordinary Shares were bought for her SIPP at £0.68 per share.

Following this transaction, Ms Ferguson's beneficial interest in the Company remains as previously disclosed at 19,673 Ordinary Shares, representing 0.034% of the Company's issued share capital.

Enquiries:

Vernalis plc +44 (0) 118 977 3133

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

Brunswick Group +44 (0) 20 7404 5959

Jon Coles

Justine McIlroy

About Vernalis:

Vernalis is a development stage pharmaceutical company developing a pipeline of clinical and early stage programmes. The Company currently has seven product candidates in clinical development (two of which are partnered) and two programmes in pre-clinical trials (one with a partner) and other competitive research programmes. Our collaborations are with leading, global pharmaceutical companies including Biogen Idec, Novartis, Servier, Chiesi, Menarini and Endo.

For further information about Vernalis, please visit www.vernalis.com.